Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;79(4):480-482.
doi: 10.1053/j.ajkd.2022.01.001. Epub 2022 Jan 12.

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection

Steven Fishbane  1 , Jamie S Hirsch  2 , Vinay Nair  2
Affiliations
Editorial

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection

Steven Fishbane et al. Am J Kidney Dis. 2022 Apr.
No abstract available

PubMed Disclaimer

References

    1. Worobey M., Pekar J., Larsen B.B., et al. The emergence of SARS-CoV-2 in Europe and North America. Science. 2020;370(6516):564–570. - PMC - PubMed
    1. Crichton M.L., Goeminne P.C., Tuand K., et al. European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. Eur Respir Rev. 2021;30(162):210171. - PMC - PubMed
    1. Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19. https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-u...
    1. Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-n...
    1. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. https://clinicaltrials.gov/ct2/show/study/NCT04960202?term=EPIC-HR&draw=...

Publication types